Judd Apatow’s experience with Ozempic has produced an unexpected result: weight gain rather than weight loss.
During a recent appearance on Jimmy Kimmel Live!, actress Leslie Mann said her husband has gained about 15 pounds over four years while using the medication. She explained that Apatow has been deliberately pushing back against the appetite-suppressing effect he associates with the drug.
Mann made the comments while speaking with guest host Jelly Roll on the August 27 episode of the ABC late-night show. ABC’s official episode listing confirms Mann’s appearance alongside Jelly Roll.
Leslie Mann Explains Judd Apatow’s Ozempic Weight Gain
According to Mann, Apatow has gained roughly 15 pounds during the four years he has been taking Ozempic.
She said he is taking a high dose and actively tries to overcome the feeling of reduced appetite associated with the medication.
Rather than treating the loss of appetite as the main goal, Apatow has approached it almost like a personal challenge.
That unusual strategy helps explain why his experience has been so different from the weight-loss results commonly associated with GLP-1 medications.
The conversation also surprised Jelly Roll, who has spoken publicly about his own weight-loss journey and experiences with weight-loss medications.
Why Judd Apatow Says He Wanted to “Outrun” Ozempic
Apatow has previously discussed his unusual approach to Ozempic.
In earlier comments, he described his goal as trying to overcome the medication’s effects rather than simply relying on it to reduce his weight.
His comments suggest that the experiment was partly about testing whether he could continue eating despite the medication’s appetite-related effects.
The filmmaker has also joked publicly about eating while experiencing the effects of Ozempic. His remarks have framed the experience as a battle between his appetite and the medication.
In a 2024 interview with Vulture, Apatow explained that his objective was not necessarily conventional weight loss. Instead, he wanted to see whether he could continue gaining weight while taking a drug designed to help control appetite.
That history gives additional context to Mann’s latest comments.
What Ozempic Is Designed to Do
Ozempic contains semaglutide, a GLP-1 receptor agonist. According to the U.S. Food and Drug Administration’s current prescribing information, Ozempic is approved for specific uses involving adults with Type 2 diabetes and related cardiovascular risk reduction.
Semaglutide can affect appetite and food intake, but individual experiences can vary.
The FDA lists nausea, vomiting, diarrhoea, abdominal pain and constipation among the most common adverse reactions associated with Ozempic. The prescribing information also warns about potentially serious gastrointestinal reactions.
Therefore, Apatow’s experience should not be treated as evidence that Ozempic generally causes weight gain. His comments describe his personal experience and behaviour while taking the medication.
Judd Apatow’s Story Is Different From the Typical Ozempic Conversation
Ozempic and other GLP-1 medications have become a major part of the public conversation about weight management.
Many discussions focus on appetite reduction and weight loss. Apatow’s story stands out because he has openly described trying to counter those effects.
His comments also highlight an important distinction between a medication’s intended effects and how an individual chooses to respond to them.
In Apatow’s case, Mann says he has been intentionally trying to override the reduced appetite he experiences.
That makes his situation unusual, but it does not change how the medication is medically intended to work.
Leslie Mann’s Comments Add a New Chapter to Apatow’s Ozempic Experiment
Mann’s latest comments are notable because they provide an update on an experiment Apatow has discussed for years.
Rather than quietly using the medication as a conventional weight-loss treatment, he has repeatedly spoken about trying to challenge its effects.
His reported 15-pound weight gain now gives that long-running experiment a measurable outcome, at least according to Mann’s account.
The comments were made in a light-hearted late-night television setting, so they should be understood as a description of Apatow’s personal experience rather than medical advice.
Anyone considering Ozempic or another GLP-1 medication should discuss the appropriate treatment and dosage with a qualified healthcare professional.
The Bigger Picture Around GLP-1 Medications
The growing popularity of GLP-1 medications has also created a broader discussion about weight, appetite, health and expectations surrounding treatment.
Apatow’s experience illustrates why celebrity stories can provide only limited insight into how these medications work for other people.
Medication response can differ from person to person. In addition, Ozempic has specific approved indications and safety considerations that should be evaluated by healthcare professionals.
For now, Apatow’s story remains an unusual example of someone who says he has tried to work against the appetite effects of a medication rather than simply embracing them.
What Happens Next for Judd Apatow?
Mann’s comments suggest that Apatow is still taking Ozempic despite his lack of conventional weight-loss results.
For someone who has openly treated the medication as a personal challenge, the reported weight gain adds another unexpected chapter to the story.
Whether Apatow eventually changes his approach remains unclear. For now, his experience is notable largely because he has been unusually candid about his reasons for taking the drug and his efforts to resist its appetite-related effects.